Guidelines on the acute and long-term pharmacological treatment of acute mesenteric ischaemia (AMI) recommend the use of thrombolytic, antiplatelet or anticoagulant therapy depending on the aetiology of AMI and the use of stenting but only few details are given on the choice of the drug, dose and duration of treatment. Besides, recommendations are mainly based on data on coronary, cerebral and other peripheral artery diseases and do also not take into account the altered drug absorption in patients with short bowel syndrome, in which AMI can result.This case-based survey will inform us on the current international clinical practice of long-term antithrombotic management of AMI.
Study Type
OBSERVATIONAL
Enrollment
51
Online survey questioning the current clinical practice on long-term antithrombotic management of AMI in SBS patients
University Hospitals Leuven
Leuven, Belgium
Type of antithrombotic therapy
Overview of the type of long-term antithrombotic therapy that is prescribed in SBS patients with AMI, depending on the anatomy of the gastrointestinal tract, the aetiology of AMI and whether or not revascularisation of the occluding blood vessel has been performed
Time frame: April 2023
Duration of antithrombotic therapy
Overview of the duration of long-term antithrombotic therapy in SBS patients with AMI depending on the anatomy of the gastrointestinal tract, the aetiology of AMI and whether or not revascularisation of the occluding blood vessel has been performed.
Time frame: April 2023
Initial dose of antithrombotic therapy
Overview of the initial dose of long-term antithrombotic therapy in SBS patients with AMI depending on the anatomy of the gastrointestinal tract, the aetiology of AMI and whether or not revascularisation of the occluding blood vessel has been performed.
Time frame: April 2023
Dose adjustments of antithrombotic therapy
Overview of any dose adjustments of long-term antithrombotic therapy in SBS patients with AMI depending on the anatomy of the gastrointestinal tract, the aetiology of AMI and whether or not revascularisation of the occluding blood vessel has been performed.
Time frame: April 2023
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.